Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mortality and re-fracture rates in low trauma hip fracture.
Mohseni V, Fahimfar N, Ansarifar A, Masoumi S, Sanjari M, Khalagi K, Bagherifard A, Larijani B, Janani L, Mansourzadeh MJ, Ostovar A, Solaymani-Dodaran M. Mohseni V, et al. Among authors: ansarifar a. BMC Geriatr. 2024 Apr 30;24(1):381. doi: 10.1186/s12877-024-04950-1. BMC Geriatr. 2024. PMID: 38684943 Free PMC article.
Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: A phase III, non-inferiority trial.
Solaymani-Dodaran M, Kalantari S, Banihashemi SR, Es-Haghi A, Nofeli M, Mohazzab A, Mokhberalsafa L, Sadeghi F, Mokaram AR, Moradi MH, Razaz SH, Taghdiri M, Lotfi M, Setarehdan SA, Masoumi S, Ansarifar A, Ebrahimi S, Esmailzadehha N, Boluki Z, Khoramdad M, Molaipour L, Rabiei MH, Amiri FB, Filsoof S, Bani-Vaheb B, Derakhshani MR, Bayazidi S, Golmoradizadeh R, Shahsavan M, Safari S, Ghahremanzadeh N, Mohseni V, Erfanpoor S, Fallah Mehrabadi MH. Solaymani-Dodaran M, et al. Among authors: ansarifar a. Heliyon. 2024 Mar 3;10(5):e27370. doi: 10.1016/j.heliyon.2024.e27370. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463808 Free PMC article.
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
Erfanpoor S, Banihashemi SR, Mokhbaeralsafa L, Kalantari S, Es-Haghi A, Nofeli M, Rezaei Mokarram A, Sadeghi F, Hajimoradi M, Razaz SH, Taghdiri M, Lotfi M, Khorasani A, Ansarifar A, Masoumi S, Mohazzab A, Filsoof S, Mohseni V, Shahsavan M, Gharavi N, Setarehdan SA, Rabiee MH, Fallah Mehrabadi MH, Solaymani-Dodaran M. Erfanpoor S, et al. Among authors: ansarifar a. BMC Med. 2024 Feb 20;22(1):78. doi: 10.1186/s12916-024-03295-1. BMC Med. 2024. PMID: 38378570 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial.
Ansarifar A, Farahani RH, Rahjerdi AK, Ahi M, Sheidaei A, Gohari K, Rahimi Z, Gholami F, Basiri P, Moradi M, Jahangiri A, Naderi K, Ghasemi S, Khatami P, Honari M, Khodaverdloo S, Shooshtari M, Azin HM, Moradi S, Shafaghi B, Allahyari H, Monazah A, Poor AK, Bakhshande H, Taghva Z, Nia MK, Dodaran MS, Foroughizadeh M. Ansarifar A, et al. Vaccine X. 2023 Oct 27;15:100401. doi: 10.1016/j.jvacx.2023.100401. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37941802 Free PMC article.
Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18-70 Years; A Randomized, Double-Blind Clinical Trial.
Mohazzab A, Fallah Mehrabadi MH, Es-Haghi A, Kalantari S, Mokhberalsafa L, Setarehdan SA, Sadeghi F, Rezaei Mokarram A, Haji Moradi M, Razaz SH, Taghdiri M, Ansarifar A, Lotfi M, Khorasani A, Nofeli M, Masoumi S, Boluki Z, Erfanpoor S, Bagheri Amiri F, Esmailzadehha N, Filsoof S, Mohseni V, Ghahremanzadeh N, Safari S, Shahsavan M, Bayazidi S, Raghami Derakhshani M, Rabiee MH, Golmoradi-Zadeh R, Khodadoost B, Solaymani-Dodaran M, Banihashemi SR. Mohazzab A, et al. Among authors: ansarifar a. J Pharm Sci. 2023 Dec;112(12):3012-3021. doi: 10.1016/j.xphs.2023.09.027. Epub 2023 Oct 11. J Pharm Sci. 2023. PMID: 37832918 Clinical Trial.
Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial.
Solaymani-Dodaran M, Basiri P, Moradi M, Gohari K, Sheidaei A, Ahi M, Ghafoori Naeeni F, Ansarifar A, Rahimi Z, Gholami F, Karimi Rahjerdi A, Hamidi Farahani R, Naderi Saffar K, Ghasemi S, Shooshtari A, Honari M, Mozafari A, Khodaverdloo S, Forooghizadeh M. Solaymani-Dodaran M, et al. Among authors: ansarifar a. Virol J. 2023 Jul 18;20(1):154. doi: 10.1186/s12985-023-02121-z. Virol J. 2023. PMID: 37464440 Free PMC article. Clinical Trial.
Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial.
Dodaran MS, Banihashemi SR, Es-Haghi A, Mehrabadi MHF, Nofeli M, Mokarram AR, Mokhberalsafa L, Sadeghi F, Ranjbar A, Ansarifar A, Mohazzab A, Setarehdan SA, Bagheri Amiri F, Mohseni V, Hajimoradi M, Ghahremanzadeh N, Razzaz SH, Masoomi S, Taghdiri M, Bagheri M, Lofti M, Khorasani A, Ghader M, Safari S, Shahsavn M, Kalantari S. Dodaran MS, et al. Among authors: ansarifar a. Vaccines (Basel). 2023 Feb 16;11(2):455. doi: 10.3390/vaccines11020455. Vaccines (Basel). 2023. PMID: 36851334 Free PMC article.
Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.
Gholami F, Hamidi Farahani R, Karimi Rahjerdi A, Ahi M, Sheidaei A, Gohari K, Rahimi Z, Ansarifar A, Basiri P, Moradi M, Jahangiri A, Naderi K, Ghasemi S, Khatami P, Honari M, Khodaverdloo S, Shooshtari M, Mehr Azin H, Moradi S, Shafaghi B, Allahyari H, Monazah A, Khodaei Poor A, Taghva Z, Bakhshande H, Karimi Nia M, Solaymani Dodaran M, Forooghizade M. Gholami F, et al. Among authors: ansarifar a. BMC Infect Dis. 2023 Feb 24;23(1):118. doi: 10.1186/s12879-023-08079-1. BMC Infect Dis. 2023. PMID: 36829111 Free PMC article. Clinical Trial.
The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial.
Ghanei M, Solaymani-Dodaran M, Qazvini A, Ghazale AH, Setarehdan SA, Saadat SH, Ghobadi H, Hoseininia S, Elahikhah M, Samadi AH, Imani Y, Vahedi E, Babamahmoodi F, Rostami FT, Ardebili MHA, Ansarifar A, Golmaei FF, Asadollah A. Ghanei M, et al. Among authors: ansarifar a. Respir Res. 2021 Sep 15;22(1):245. doi: 10.1186/s12931-021-01833-6. Respir Res. 2021. PMID: 34526033 Free PMC article. Clinical Trial.
12 results